Read More Pharma Industry News Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s… byPallavi MadhirajuJanuary 31, 2024